14 research outputs found
Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose
BACKGROUND: Apramycin is under development for human use as EBL-1003, a crystalline free base of apramycin, in face of increasing incidence of multidrug-resistant bacteria. Both toxicity and cross-resistance, commonly seen for other aminoglycosides, appear relatively low owing to its distinct chemical structure.
OBJECTIVES: To perform a population pharmacokinetic (PPK) analysis and predict an efficacious dose based on data from a first-in-human Phase I trial.
METHODS: The drug was administered intravenously over 30â
min in five ascending-dose groups ranging from 0.3 to 30â
mg/kg. Plasma and urine samples were collected from 30 healthy volunteers. PPK model development was performed stepwise and the final model was used for PTA analysis.
RESULTS: A mammillary four-compartment PPK model, with linear elimination and a renal fractional excretion of 90%, described the data. Apramycin clearance was proportional to the absolute estimated glomerular filtration rate (eGFR). All fixed effect parameters were allometrically scaled to total body weight (TBW). Clearance and steady-state volume of distribution were estimated to 5.5â
L/h and 16â
L, respectively, for a typical individual with absolute eGFR of 124â
mL/min and TBW of 70â
kg. PTA analyses demonstrated that the anticipated efficacious dose (30â
mg/kg daily, 30â
min intravenous infusion) reaches a probability of 96.4% for a free AUC/MIC target of 40, given an MIC of 8â
mg/L, in a virtual Phase II patient population with an absolute eGFR extrapolated to 80â
mL/min.
CONCLUSIONS: The results support further Phase II clinical trials with apramycin at an anticipated efficacious dose of 30â
mg/kg once daily
Clinical-Pharmacokinetic Aspects of Prolonged Effect Duration as Illustrated by ÎČ2-Agonists
Regularity is a key element of maintenance drug treatment; compliance is crucial for treatment success. Once- or twice-daily intake of a drug is always easier to comply with than regimens requiring more frequent dosing. Bronchodilating treatment was used as an example to illustrate how sustained duration of effect can be achieved by two different approaches: oral administration of the terbutaline prodrug bambuterol and inhalation of formoterol. Bioanalytical methods were employed to monitor the kinetic fate of bambuterol and formoterol in plasma, urine, or faeces. Generated terbutaline in plasma was used as a marker of effect for bambuterol. Established clinical laboratory tests were used to assess local and systemic effects of inhaled formoterol compared with salbutamol. Recommended doses of bambuterol, 10-20 mg once daily in adults, normally produced plasma concentrations of the active moiety terbutaline within therapeutically relevant limits. Dose proportionality for terbutaline makes dosing with bambuterol predictable. Compared with adults, children should be given higher doses than indicated by their lower body weight. Pharmacokinetic analysis indicated that absorption of bambuterol was slow and multi-phasic and that slow biotransformation to terbutaline occurred both presystemically and systemically. Systemically circulating formoterol was rapidly eliminated, the inactive (S;S)-formoterol more rapidly than the active (R;R)-formoterol. An inactive phenol glucuronide was the main metabolite, and a previously unknown sulphate metabolite was discovered. Duration of systemically mediated cardiovascular or metabolic side-effects of inhaled formoterol seemed not to differ from those of an inhaled systemically equieffective dose of salbutamol. There was a trend suggesting that the magnitude of systemic side-effects may be less pronounced after inhalation of formoterol compared with a locally equieffective dose of inhaled salbutamol. Both approaches to sustaining stimulation of ÎČ2-adrenoceptors have their pros and cons. Bambuterol can be dosed orally once daily, but full effect is reached slowly. The effect of formoterol is reached within a few minutes, but administration must occur via the lungs, often twice daily. Both treatments, however, give 24-h symptom relief during regular treatment
Om fattigdomen och allmÀnna fattigvÄrden i Finland: akademisk afhandling, som med tillstÄnd af den vidtlagfarna juridiska fakulteten vid Kejserliga Alexanders-Universitetet i Finland till granskning framstÀlles af Johan Wilhelm Rosenborg, juris licenciat, i. hist.-filol. lÀrosalen den 29 September 1858
Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra long-acting ÎČ2-adrenoceptor agonist (uLABA), with formoterol in patients with asthma.
Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with ÎČ2-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This single-dose crossover study was conducted to investigate and compare with formoterol the bronchodilatory and systemic effects, tolerability and safety of AZD3199, a novel ultra-long-acting ÎČ2-agonist (uLABA)
Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting ÎČ2-adrenoreceptor agonist (uLABA).
The clinical pharmacokinetics of AZD3199, an ultra-long-acting ÎČ2-agonist, were investigated in healthy volunteers and patients with asthma or chronic obstructive pulmonary disease (COPD)
Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose
Background Apramycin is under development for human use as EBL-1003, a crystalline free base of apramycin, in face of increasing incidence of multidrug-resistant bacteria. Both toxicity and cross-resistance, commonly seen for other aminoglycosides, appear relatively low owing to its distinct chemical structure. Objectives To perform a population pharmacokinetic (PPK) analysis and predict an efficacious dose based on data from a first-in-human Phase I trial. Methods The drug was administered intravenously over 30 min in five ascending-dose groups ranging from 0.3 to 30 mg/kg. Plasma and urine samples were collected from 30 healthy volunteers. PPK model development was performed stepwise and the final model was used for PTA analysis. Results A mammillary four-compartment PPK model, with linear elimination and a renal fractional excretion of 90%, described the data. Apramycin clearance was proportional to the absolute estimated glomerular filtration rate (eGFR). All fixed effect parameters were allometrically scaled to total body weight (TBW). Clearance and steady-state volume of distribution were estimated to 5.5 L/h and 16 L, respectively, for a typical individual with absolute eGFR of 124 mL/min and TBW of 70 kg. PTA analyses demonstrated that the anticipated efficacious dose (30 mg/kg daily, 30 min intravenous infusion) reaches a probability of 96.4% for a free AUC/MIC target of 40, given an MIC of 8 mg/L, in a virtual Phase II patient population with an absolute eGFR extrapolated to 80 mL/min. Conclusions The results support further Phase II clinical trials with apramycin at an anticipated efficacious dose of 30 mg/kg once daily